Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Family history of breast cancer and its association with disease severity and mortality.

Melvin JC, Wulaningsih W, Hana Z, Purushotham AD, Pinder SE, Fentiman I, Gillett C, Mera A, Holmberg L, Van Hemelrijck M.

Cancer Med. 2016 May;5(5):942-9. doi: 10.1002/cam4.648. Epub 2016 Jan 22.

2.

DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.

Yang RL, Mick R, Lee K, Graves HL, Nathanson KL, Domchek SM, Kelz RR, Zhang PJ, Czerniecki BJ.

J Transl Med. 2015 Oct 24;13:335. doi: 10.1186/s12967-015-0698-3.

3.

Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer.

Bayraktar S, Qiu H, Liu D, Shen Y, Gutierrez-Barrera AM, Arun BK, Sahin AA.

Biomark Cancer. 2015 Aug 18;7:39-49. doi: 10.4137/BIC.S29716. eCollection 2015.

4.

Immunoprofile from tissue microarrays to stratify familial breast cancer patients.

Schirosi L, De Summa S, Tommasi S, Paradiso A, Sambiasi D, Popescu O, Simone G, Mangia A.

Oncotarget. 2015 Sep 29;6(29):27865-79. doi: 10.18632/oncotarget.4720.

5.

Genotype/Phenotype correlations in patients with hereditary breast cancer.

Wittersheim M, Büttner R, Markiefka B.

Breast Care (Basel). 2015 Feb;10(1):22-6. doi: 10.1159/000380900. Review.

6.

Histologic features of melanoma associated with CDKN2A genotype.

Sargen MR, Kanetsky PA, Newton-Bishop J, Hayward NK, Mann GJ, Gruis NA, Tucker MA, Goldstein AM, Bianchi-Scarra G, Puig S, Elder DE.

J Am Acad Dermatol. 2015 Mar;72(3):496-507.e7. doi: 10.1016/j.jaad.2014.11.014. Epub 2015 Jan 13.

7.

Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.

Brewster AM, Chavez-MacGregor M, Brown P.

Lancet Oncol. 2014 Dec;15(13):e625-34. doi: 10.1016/S1470-2045(14)70364-X. Epub 2014 Nov 24. Review.

8.

Hereditary breast cancer: clinical, pathological and molecular characteristics.

Larsen MJ, Thomassen M, Gerdes AM, Kruse TA.

Breast Cancer (Auckl). 2014 Oct 15;8:145-55. doi: 10.4137/BCBCR.S18715. eCollection 2014. Review.

9.

Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features.

Pang JM, Deb S, Takano EA, Byrne DJ, Jene N, Boulghourjian A, Holliday A, Millar E, Lee CS, O'Toole SA, Dobrovic A, Fox SB.

Breast Cancer Res. 2014 Oct 21;16(5):423. doi: 10.1186/s13058-014-0423-9.

10.

BRCA1 pathway function in basal-like breast cancer cells.

Hill SJ, Clark AP, Silver DP, Livingston DM.

Mol Cell Biol. 2014 Oct;34(20):3828-42. doi: 10.1128/MCB.01646-13. Epub 2014 Aug 4.

11.

Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy.

van Verschuer VM, Heemskerk-Gerritsen BA, van Deurzen CH, Obdeijn IM, Tilanus-Linthorst MM, Verhoef C, Schmidt MK, Koppert LB, Hooning MJ, Seynaeve C.

Cancer Biol Ther. 2014 Apr;15(4):371-9. doi: 10.4161/cbt.27628. Epub 2014 Jan 14.

12.

A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.

Karami F, Mehdipour P.

Biomed Res Int. 2013;2013:928562. doi: 10.1155/2013/928562. Epub 2013 Nov 7. Review.

13.

Breast cancer in systemic lupus erythematosus.

Tessier Cloutier B, Clarke AE, Ramsey-Goldman R, Wang Y, Foulkes W, Gordon C, Hansen JE, Yelin E, Urowitz MB, Gladman D, Fortin PR, Wallace DJ, Petri M, Manzi S, Ginzler EM, Labrecque J, Edworthy S, Dooley MA, Senécal JL, Peschken CA, Bae SC, Isenberg D, Rahman A, Ruiz-Irastorza G, Hanly JG, Jacobsen S, Nived O, Witte T, Criswell LA, Barr SG, Dreyer L, Sturfelt G, Bernatsky S.

Oncology. 2013;85(2):117-21. doi: 10.1159/000353138. Epub 2013 Jul 25.

14.

Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.

Larsen MJ, Kruse TA, Tan Q, Lænkholm AV, Bak M, Lykkesfeldt AE, Sørensen KP, Hansen TV, Ejlertsen B, Gerdes AM, Thomassen M.

PLoS One. 2013 May 21;8(5):e64268. doi: 10.1371/journal.pone.0064268. Print 2013.

15.

HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.

van der Groep P, van Diest PJ, Smolders YH, Ausems MG, van der Luijt RB, Menko FH, Bart J, de Vries EG, van der Wall E.

PLoS One. 2013;8(2):e56055. doi: 10.1371/journal.pone.0056055. Epub 2013 Feb 8.

16.

Genomic insights into cancer-associated aberrant CpG island hypermethylation.

Sproul D, Meehan RR.

Brief Funct Genomics. 2013 May;12(3):174-90. doi: 10.1093/bfgp/els063. Epub 2013 Jan 21. Review.

17.

Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry.

Mulligan AM, Raitman I, Feeley L, Pinnaduwage D, Nguyen LT, O'Malley FP, Ohashi PS, Andrulis IL.

Clin Cancer Res. 2013 Jan 15;19(2):336-46. doi: 10.1158/1078-0432.CCR-11-3314. Epub 2012 Dec 4.

18.

Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.

Fujiwara M, McGuire VA, Felberg A, Sieh W, Whittemore AS, Longacre TA.

Am J Surg Pathol. 2012 Aug;36(8):1170-7. doi: 10.1097/PAS.0b013e31825d9b8d.

19.

Triple-negative breast cancer: adjuvant therapeutic options.

Gucalp A, Traina TA.

Chemother Res Pract. 2011;2011:696208. doi: 10.1155/2011/696208. Epub 2011 Jun 21.

20.

Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.

Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, Ursin G.

J Clin Oncol. 2011 Nov 20;29(33):4373-80. doi: 10.1200/JCO.2010.33.6446. Epub 2011 Oct 17.

Items per page

Supplemental Content

Write to the Help Desk